SG Americas Securities LLC Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

SG Americas Securities LLC lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 91,078 shares of the medical equipment provider’s stock after selling 12,384 shares during the period. SG Americas Securities LLC’s holdings in Zimmer Biomet were worth $8,235,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Main Management ETF Advisors LLC boosted its holdings in Zimmer Biomet by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 112 shares during the period. Boltwood Capital Management increased its holdings in shares of Zimmer Biomet by 3.9% in the fourth quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock worth $348,000 after purchasing an additional 144 shares during the period. Independence Bank of Kentucky raised its position in shares of Zimmer Biomet by 9.7% in the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock worth $147,000 after buying an additional 145 shares in the last quarter. LOM Asset Management Ltd raised its position in shares of Zimmer Biomet by 21.5% in the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 147 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. boosted its stake in Zimmer Biomet by 5.9% during the third quarter. Mesirow Financial Investment Management Inc. now owns 2,723 shares of the medical equipment provider’s stock valued at $268,000 after buying an additional 151 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZBH. Truist Financial restated a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Robert W. Baird set a $92.00 price target on Zimmer Biomet in a report on Wednesday, April 29th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Trading Up 2.2%

NYSE ZBH opened at $92.92 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $86.78 and its two-hundred day simple moving average is $89.99. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The company has a market capitalization of $17.98 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 2.74 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.